A small progression-free survival advantage is similarly found for patients with locally advanced/metastatic HER2-negative, BRCA germline-mutated breast cancer; however, the authors are more hesitant to implore strong recommendations for clinical use, particularly as monotherapy, perhaps due to the emergence of other meta-analyses that investigate different PARP inhibitors [161]. The gene discussed is ERBB2; the disease is breast cancer.